

Massimiliano Di Filippo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3662483/publications.pdf>

Version: 2024-02-01

105
papers

6,746
citations

81900

39
h-index

66911

78
g-index

106
all docs

106
docs citations

106
times ranked

10153
citing authors

#	ARTICLE	IF	CITATIONS
1	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 448-450.	1.9	53
2	The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. Journal of Neurology, 2022, 269, 3129-3135.	3.6	6
3	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. Journal of Neurology, 2022, 269, 3301-3307.	3.6	9
4	Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements. Biomolecules, 2022, 12, 677.	4.0	2
5	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28, 2106-2111.	3.0	30
6	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. European Journal of Neurology, 2021, 28, 1299-1307.	3.3	12
7	Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. Neural Regeneration Research, 2021, 16, 36.	3.0	23
8	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. Journal of Neurology, 2021, 268, 2922-2932.	3.6	18
9	Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction. Frontiers in Immunology, 2021, 12, 644294.	4.8	16
10	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. International Journal of Molecular Sciences, 2021, 22, 4440.	4.1	17
11	Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. Frontiers in Neuroscience, 2021, 15, 672954.	2.8	19
12	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. Journal of the Neurological Sciences, 2021, 424, 117430.	0.6	1
13	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. Cells, 2021, 10, 1930.	4.1	34
14	Editorial: Cognition in Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 751687.	2.4	4
15	A blood test for Alzheimer's disease: a step forward. Lancet Neurology, The, 2021, 20, 691-693.	10.2	1
16	Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection. International Journal of Molecular Sciences, 2021, 22, 9753.	4.1	17
17	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Reports, 2021, 37, 110094.	6.4	38
18	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. Multiple Sclerosis and Related Disorders, 2020, 37, 101461.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 339, 577108.	2.3	31
20	An “all-wheel drive” proposal to accelerate clinical research in common and rare neurological diseases. <i>Neurological Sciences</i> , 2020, 41, 789-793.	1.9	0
21	Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. <i>European Journal of Neurology</i> , 2020, 27, 633-643.	3.3	29
22	From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson’s Disease: Lessons From LRRK2. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 158.	3.7	15
23	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the irems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.	2.0	2
24	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 1023-1037.	8.7	48
25	Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 157.	4.8	35
26	Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3848-3857.	7.1	58
27	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020, 41, 2249-2253.	1.9	0
28	Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. <i>Neurobiology of Disease</i> , 2020, 140, 104848.	4.4	19
29	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 228-232.	2.0	20
30	Hippocampal epileptogenesis in autoimmune encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2261-2269.	3.7	20
31	Serum neurofilament light chain as a preclinical marker of neurodegeneration. <i>Lancet Neurology</i> , The, 2019, 18, 1070-1071.	10.2	9
32	Beyond clinical changes: Rehabilitation-induced neuroplasticity in MS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1348-1362.	3.0	47
33	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2157-2163.	3.6	41
34	“Better explanations” in multiple sclerosis diagnostic workup. <i>Neurology</i> , 2019, 92, e2527-e2537.	1.1	44
35	Neurofilament light chain as a biomarker in neurological disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 870-881.	1.9	623
36	Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. <i>Brain</i> , 2019, 142, 1365-1385.	7.6	82

#	ARTICLE	IF	CITATIONS
37	Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis. <i>Neural Regeneration Research</i> , 2019, 14, 77.	3.0	4
38	Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. <i>Journal of Neurology</i> , 2018, 265, 522-529.	3.6	5
39	Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. <i>Neurobiology of Disease</i> , 2018, 113, 97-108.	4.4	27
40	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 8.	6.2	111
41	Lacosamide protects striatal and hippocampal neurons from in vitro ischemia without altering physiological synaptic plasticity. <i>Neuropharmacology</i> , 2018, 135, 424-430.	4.1	13
42	A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018, 265, 1174-1183.	3.6	23
43	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. <i>Journal of Neurology</i> , 2018, 265, 2684-2687.	3.6	35
44	Multiple sclerosis and cognition: synaptic failure and network dysfunction. <i>Nature Reviews Neuroscience</i> , 2018, 19, 599-609.	10.2	151
45	Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 118, 1-8.	4.4	22
46	A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. <i>Journal of Neurology</i> , 2017, 264, 973-978.	3.6	18
47	Visual pathway involvement in multiple sclerosis: Look straight in the eyes. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 217-219.	2.0	5
48	Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	19
49	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. <i>Journal of the Neurological Sciences</i> , 2017, 379, 236-240.	0.6	12
50	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. <i>Journal of Neurology</i> , 2016, 263, 1449-1451.	3.6	2
51	Epilepsy, amyloid- β , and D1 dopamine receptors: a possible pathogenetic link?. <i>Neurobiology of Aging</i> , 2016, 48, 161-171.	3.1	71
52	Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. <i>European Neurology</i> , 2016, 76, 62-68.	1.4	4
53	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. <i>Scientific Reports</i> , 2016, 6, 20926.	3.3	68
54	Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit. <i>Biological Psychiatry</i> , 2016, 79, 402-414.	1.3	77

#	ARTICLE	IF	CITATIONS
55	Interferon- β 1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors. <i>Neuropharmacology</i> , 2016, 100, 98-105.	4.1	17
56	Retinopathy during interferon- β treatment for multiple sclerosis: case report and review of the literature. <i>Journal of Neurology</i> , 2016, 263, 422-427.	3.6	12
57	Endogenous 17 β -estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 192.	3.7	43
58	Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. <i>Brain Research</i> , 2015, 1621, 205-213.	2.2	30
59	The changing tree in Parkinson's disease. <i>Nature Neuroscience</i> , 2015, 18, 1196-1198.	14.8	7
60	Multitarget disease-modifying therapy in Parkinson's disease?. <i>Lancet Neurology</i> , The, 2015, 14, 975-976.	10.2	16
61	Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 123-133.	3.1	30
62	Ischemic Stroke Injury Is Mediated by Aberrant Cdk5. <i>Journal of Neuroscience</i> , 2014, 34, 8259-8267.	3.6	73
63	Infliximab monotherapy for neuro-Behçet's disease: A case report. <i>Journal of the Neurological Sciences</i> , 2014, 347, 389-390.	0.6	8
64	Interferon- β 1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence. <i>Neurobiology of Disease</i> , 2014, 62, 387-393.	4.4	17
65	Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis. <i>European Journal of Neurology</i> , 2014, 21, 648-653.	3.3	17
66	Direct and indirect pathways of basal ganglia: a critical reappraisal. <i>Nature Neuroscience</i> , 2014, 17, 1022-1030.	14.8	598
67	New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. <i>Lancet Neurology</i> , The, 2013, 12, 811-821.	10.2	165
68	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. <i>Neurobiology of Disease</i> , 2013, 52, 229-236.	4.4	155
69	Ischemic-LTP in Striatal Spiny Neurons of both Direct and Indirect Pathway Requires the Activation of D1-Like Receptors and NO/Soluble Guanylate Cyclase/cGMP Transmission. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 278-286.	4.3	13
70	New synaptic and molecular targets for neuroprotection in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 51-60.	3.9	34
71	A pathophysiological link between dystonia, striatal interneurons and neuropeptide Y. <i>Brain</i> , 2013, 136, 1341-1344.	7.6	3
72	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18985-18990.	7.1	113

#	ARTICLE	IF	CITATIONS
73	A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. PLoS ONE, 2012, 7, e38312.	2.5	18
74	Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain, 2012, 135, 1884-1899.	7.6	124
75	Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis. Journal of Neurology, 2011, 258, 323-324.	3.6	12
76	Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain, 2011, 134, 375-387.	7.6	125
77	The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D ₂ /A _{2A} Receptor Interaction in the Striatum: Implications for Parkinson's Disease. Journal of Neuroscience, 2011, 31, 1850-1862.	3.6	140
78	Mitochondria and the Link Between Neuroinflammation and Neurodegeneration. Journal of Alzheimer's Disease, 2010, 20, S369-S379.	2.6	118
79	A young patient with type C multiple system atrophy and hereditary hemochromatosis. Journal of Neurology, 2010, 257, 294-295.	3.6	3
80	Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurology, The, 2010, 9, 1106-1117.	10.2	329
81	Brain's traffic lights. Nature, 2010, 466, 449-449.	27.8	10
82	Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition. Journal of Neuroscience, 2010, 30, 14182-14193.	3.6	155
83	Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 204-208.	1.9	79
84	Impaired Plasticity at Specific Subset of Striatal Synapses in the Ts65Dn Mouse Model of Down Syndrome. Biological Psychiatry, 2010, 67, 666-671.	1.3	28
85	Hippocampal Synaptic Plasticity, Memory, and Epilepsy: Effects of Long-Term Valproic Acid Treatment. Biological Psychiatry, 2010, 67, 567-574.	1.3	68
86	Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. European Journal of Neuroscience, 2009, 29, 1979-1993.	2.6	26
87	Short-term and long-term plasticity at corticostriatal synapses: Implications for learning and memory. Behavioural Brain Research, 2009, 199, 108-118.	2.2	115
88	CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. European Journal of Neurology, 2008, 15, 998-1001.	3.3	34
89	Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neuroscience Letters, 2008, 435, 223-228.	2.1	52
90	ACh/Dopamine Crosstalk in Motor Control and Reward: A Crucial Role for $\alpha 6$ -Containing Nicotinic Receptors?. Neuron, 2008, 60, 4-7.	8.1	22

#	ARTICLE	IF	CITATIONS
91	Plasticity and repair in the post-ischemic brain. <i>Neuropharmacology</i> , 2008, 55, 353-362.	4.1	132
92	Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. <i>Neuropharmacology</i> , 2008, 55, 223-229.	4.1	25
93	Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 402-412.	8.7	172
94	Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. <i>Brain</i> , 2008, 132, 285-287.	7.6	50
95	The Endocannabinoid System in Parkinsons Disease. <i>Current Pharmaceutical Design</i> , 2008, 14, 2337-2346.	1.9	52
96	Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition. <i>Journal of Neuroscience</i> , 2008, 28, 8040-8052.	3.6	54
97	Na ⁺ /Ca ²⁺ Exchanger Maintains Ionic Homeostasis in the Peri-Infarct Area. <i>Stroke</i> , 2007, 38, 1614-1620.	2.0	11
98	Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon- β 1a, and high doses of immunoglobulins. <i>Multiple Sclerosis Journal</i> , 2007, 13, 313-331.	3.0	58
99	Dopamine-mediated regulation of corticostriatal synaptic plasticity. <i>Trends in Neurosciences</i> , 2007, 30, 211-219.	8.6	707
100	Plastic abnormalities in experimental Huntington's disease. <i>Current Opinion in Pharmacology</i> , 2007, 7, 106-111.	3.5	30
101	Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2007, 188, 146-158.	2.3	41
102	Sensitization, glutamate, and the link between migraine and fibromyalgia. <i>Current Pain and Headache Reports</i> , 2007, 11, 343-351.	2.9	95
103	Pathways of neurodegeneration and experimental models of basal ganglia disorders: Downstream effects of mitochondrial inhibition. <i>European Journal of Pharmacology</i> , 2006, 545, 65-72.	3.5	22
104	A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. <i>Lancet Neurology</i> , The, 2006, 5, 974-983.	10.2	289
105	Multiple Mechanisms Underlying the Neuroprotective Effects of Antiepileptic Drugs Against In Vitro Ischemia. <i>Stroke</i> , 2006, 37, 1319-1326.	2.0	95